Capricor Therapeutics (CAPR) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to 0.66.
- Capricor Therapeutics' Equity Ratio fell 968.22% to 0.66 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.66, marking a year-over-year decrease of 968.22%. This contributed to the annual value of 0.85 for FY2024, which is 12173.27% up from last year.
- According to the latest figures from Q3 2025, Capricor Therapeutics' Equity Ratio is 0.66, which was down 968.22% from 0.79 recorded in Q2 2025.
- In the past 5 years, Capricor Therapeutics' Equity Ratio ranged from a high of 0.85 in Q4 2024 and a low of 0.05 during Q3 2023
- Over the past 5 years, Capricor Therapeutics' median Equity Ratio value was 0.38 (recorded in 2023), while the average stood at 0.5.
- As far as peak fluctuations go, Capricor Therapeutics' Equity Ratio crashed by 11682.08% in 2023, and later surged by 162631.09% in 2024.
- Capricor Therapeutics' Equity Ratio (Quarter) stood at 0.76 in 2021, then crashed by 69.0% to 0.24 in 2022, then skyrocketed by 63.56% to 0.38 in 2023, then skyrocketed by 121.73% to 0.85 in 2024, then decreased by 22.26% to 0.66 in 2025.
- Its Equity Ratio was 0.66 in Q3 2025, compared to 0.79 in Q2 2025 and 0.83 in Q1 2025.